Literature DB >> 8895520

Lack of class I HLA expression in neuroblastoma is associated with high N-myc expression and hypomethylation due to loss of the MEMO-1 locus.

N C Cheng1, M Beitsma, A Chan, I Op den Camp, A Westerveld, J Pronk, R Versteeg.   

Abstract

Class I HLA expression is low in neuroblastoma tumours and cell lines. We have recently mapped a modifier of methylation for HLA-C (MEMO-1) to chromosomal bands 1p35-36.1, a region deleted in many neuroblastomas. Hypomethylation of HLA-C is strongly correlated with allelic loss of the MEMO-1 locus. Here, we show that loss of MEMO-1 is associated with hypomethylation of both the 5' and 3' regions of class I HLA loci. We next investigated the relationship between methylation and expression of class I HLA in 28 cell lines of neuroectodermal tumours. Cell lines with hypermethylated HLA-C and HLA-A loci have relatively high expression, while most cell lines with hypomethylated loci have no or a reduced expression. It was reported earlier that high expression of c- or N-myc can suppress class I HLA expression. Remarkably, also N-myc amplification in neuroblastomas is associated with allelic loss of 1p35-36. Therefore, we have analysed the relationships between allelic loss of the MEMO-1 locus, class I HLA methylation and expression, and N-myc amplification and expression. This study shows a tight inter-relationship between these phenomena. Our data suggest a model in which hypomethylation of class I HLA due to loss of the MEMO-1 locus and high N-myc expression could collaborate in the down-regulation of class I HLA expression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8895520

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

Review 1.  Aberrant DNA methylation in human cancers.

Authors:  Wen Li; Bi-Feng Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-12-13

2.  Down-regulation of HLA-A mRNA in peripheral blood mononuclear cell of colorectal cancer.

Authors:  Ming-Chen Zhu; Yi-Jun Xu; Xiong Zou; Feng Yan
Journal:  Int J Colorectal Dis       Date:  2011-09-23       Impact factor: 2.571

Review 3.  The MYC oncogene is a global regulator of the immune response.

Authors:  Stephanie C Casey; Virginie Baylot; Dean W Felsher
Journal:  Blood       Date:  2018-03-07       Impact factor: 22.113

Review 4.  Spotlight on TAP and its vital role in antigen presentation and cross-presentation.

Authors:  Ian Mantel; Barzan A Sadiq; J Magarian Blander
Journal:  Mol Immunol       Date:  2021-12-29       Impact factor: 4.174

5.  Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma.

Authors:  T Maruyama; K Mimura; E Sato; M Watanabe; Y Mizukami; Y Kawaguchi; T Ando; H Kinouchi; H Fujii; K Kono
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

6.  HLA-A and breast cancer in West Peninsular Malaysia.

Authors:  Pooi Pooi Leong; Rohaizak Muhammad; Naqiyah Ibrahim; Soon Keng Cheong; Heng Fong Seow
Journal:  Med Oncol       Date:  2010-01-13       Impact factor: 3.064

7.  The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer.

Authors:  Kousaku Mimura; Kensuke Shiraishi; Anja Mueller; Shinichiro Izawa; Ley-Fang Kua; Jimmy So; Wei-Peng Yong; Hideki Fujii; Barbara Seliger; Rolf Kiessling; Koji Kono
Journal:  J Immunol       Date:  2013-11-15       Impact factor: 5.422

8.  Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells.

Authors:  Jan J Molenaar; Marli E Ebus; Dirk Geerts; Jan Koster; Fieke Lamers; Linda J Valentijn; Ellen M Westerhout; Rogier Versteeg; Huib N Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-12       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.